Global private equity and venture capital news and research

Royalty Pharma raises Elan bid to $6.4bn

22 May 2013

pharma_lrgPrivate equity firm Royalty Pharma has increased its offer for Elan Corporation to $12.50 per share and said the board has failed shareholders in the recent acquisition of Theravance.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016